At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 160 target
Drug / intervention
SI-B001 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of SI-B001+SI-B003 With or Without Chemotherapy (SI-B001+SI-B003± Chemotherapy) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
In Brief
A Phase 2 clinical trial evaluating SI-B001 and SI-B003 for Non-small Cell Lung Cancer. Currently recruiting, targeting 160 participants across 1 site.
Detailed Summary
Phase Ib: To observe the safety and tolerability of the combination of SI-B001 and SI-B003, and to determine the recommended dose of phase II clinical study (RP2D) in the indication of locally advanced or metastatic non-small cell lung cancer. Phase II: To evaluate the efficacy of SI-B001+SI-B003 combination with or without chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesChina
Collaborators--
Timeline
Phase 2Recruiting
20242025202620272028
First PostedJul 2023
Enrollment StartOct 2023
TodayJul 2026
Primary CompletionDec 2026
Study CompletionDec 2027
First PostedJul 18, 2023
Enrollment StartOct 30, 2023
Primary CompletionDec 1, 2026
Study CompletionDec 1, 2027
TodayJul 1, 2026
Enrollment to primary: 3.1 yearsPosted 3.0 years agoPrimary completion in 5 months
Interventions
SI-B001drug
Administration by intravenous infusion
SI-B003drug
Administration by intravenous infusion